Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/128572
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Global coagulation assays in transgender women on oral and transdermal estradiol therapy |
Author: | Lim, H.Y. Leemaqz, S.Y. Torkamani, N. Grossmann, M. Zajac, J.D. Nandurkar, H. Ho, P. Cheung, A.S. |
Citation: | Journal of Clinical Endocrinology and Metabolism, 2020; 105(7):e2369-e2377 |
Publisher: | Oxford University Press |
Issue Date: | 2020 |
ISSN: | 0021-972X 1945-7197 |
Statement of Responsibility: | Hui Yin Lim, Shalem Y. Leemaqz, Niloufar Torkamani, Mathis Grossmann, Jeffrey D. Zajac, Harshal Nandurkar, Prahlad Ho, and Ada S. Cheung |
Abstract: | Context: The thrombotic effects of estradiol therapy in transgender women are unclear. Global coagulation assays (GCA) may be better measures of hemostatic function compared with standard coagulation tests. Objective: To assess the GCA profiles of transgender women in comparison to cisgender controls and to compare how GCA differ between routes of estradiol therapy in transgender women. Design: Cross-sectional case-control study. Setting: General community. Participants: Transgender women, cisgender male and cisgender female controls. Main Outcome Measures: Citrated blood samples were analyzed for (i) whole blood thromboelastography (TEG®5000), (ii) platelet-poor plasma thrombin generation (calibrated automated thrombogram); and (iii) platelet-poor plasma fibrin generation (overall hemostatic potential assay). Mean difference (95% confidence intervals) between groups are presented. Results: Twenty-six transgender women (16 oral estradiol, 10 transdermal estradiol) were compared with 98 cisgender women and 55 cisgender men. There were no differences in serum estradiol concentration (P = 0.929) and duration of therapy (P = 0.496) between formulations. Transgender women demonstrated hypercoagulable parameters on both thromboelastography (maximum amplitude + 6.94 mm (3.55, 10.33); P < 0.001) and thrombin generation (endogenous thrombin potential + 192.62 nM.min (38.33, 326.91); P = 0.009; peak thrombin + 38.10 nM (2.27, 73.94); P = 0.034) but had increased overall fibrinolytic potential (+4.89% (0.52, 9.25); P = 0.024) compared with cisgender men. No significant changes were observed relative to cisgender women. Route of estradiol delivery or duration of use did not influence the GCA parameters. Conclusion: Transgender women on estradiol therapy demonstrated hypercoagulable GCA parameters compared with cisgender men with a shift towards cisgender female parameters. Route of estradiol delivery did not influence the GCA parameters. |
Keywords: | Global coagulation assays; coagulation; estrogen; thrombosis; transgender |
Rights: | © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com |
DOI: | 10.1210/clinem/dgaa262 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1151535 http://purl.org/au-research/grants/nhmrc/1143333 |
Published version: | http://dx.doi.org/10.1210/clinem/dgaa262 |
Appears in Collections: | Aurora harvest 8 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.